Abstract
Psoriatic arthritis (PsA) is a chronic autoimmune inflammatory disease manifested by involvement of the musculoskeletal system and skin. The manifestations of PsA tend to significantly negatively affect the quality of life of patients, ranging from common self-care tasks to the psychological-social domain.
The introduction of biological therapy has brought substantial improvement in the prognosis of patients not responding to conventional treatment. The success of affecting the tumour necrosis factor α with therapeutic monoclonal antibodies has been followed by extensive research into other potentially suitable molecules.
Secukinumab has become the first monoclonal antibody against interleukin-17A introduced into the clinical practice in PsA treatment that is capable of having an effect on the involvement of the musculoskeletal system as well as skin manifestations.